+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Cachexia - Pipeline Review, H1 2017

  • ID: 4189130
  • Report
  • March 2017
  • 43 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aphios Corp
  • GlaxoSmithKline Plc
  • MYOS RENS Technology Inc
  • Novartis AG
  • Teijin Pharma Ltd
  • VBS Pharmaceuticals
  • MORE
Cachexia - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Cachexia - Pipeline Review, H1 2017, provides an overview of the Cachexia (Musculoskeletal Disorders) pipeline landscape.

Cachexia is the dramatic weight loss and muscle atrophy seen in patients with chronic illness including type I diabetes, multiple sclerosis, HIV, cancer, and in individuals with age-associated „failure to thrive? syndrome. Symptoms include involuntary (unintentional) weight loss, skeletal muscle wasting, anorexia/loss of appetite, lowered quality of life. Treatment includes diet, nutritional supplements, exercise and medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Cachexia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cachexia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cachexia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cachexia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Cachexia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cachexia (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Cachexia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cachexia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cachexia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cachexia (Musculoskeletal Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cachexia (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cachexia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Aphios Corp
  • GlaxoSmithKline Plc
  • MYOS RENS Technology Inc
  • Novartis AG
  • Teijin Pharma Ltd
  • VBS Pharmaceuticals
  • MORE
Introduction

Cachexia - Overview

Cachexia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cachexia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cachexia - Companies Involved in Therapeutics Development

Aphios Corp

GlaxoSmithKline Plc

MYOS RENS Technology Inc

Novartis AG

Teijin Pharma Ltd

VBS Pharmaceuticals

Cachexia - Drug Profiles

ARM-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimagrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-1889 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAR Peptide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2881078 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins for Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEISARM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cachexia - Dormant Projects

Cachexia - Discontinued Products

Cachexia - Product Development Milestones

Featured News & Press Releases

Jun 04, 2002: Aphios Receives National Cancer Institute Grant For Developing Natural Cannabinoid Products for Medical Use

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Cachexia, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Cachexia - Pipeline by Aphios Corp, H1

Cachexia - Pipeline by GlaxoSmithKline Plc, H1

Cachexia - Pipeline by MYOS RENS Technology Inc, H1

Cachexia - Pipeline by Novartis AG, H1

Cachexia - Pipeline by Teijin Pharma Ltd, H1

Cachexia - Pipeline by VBS Pharmaceuticals, H1

Cachexia - Dormant Projects, H1

Cachexia - Discontinued Products, H1

List of Figures:

Number of Products under Development for Cachexia, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
4 of 5
  • Aphios Corp
  • GlaxoSmithKline Plc
  • MYOS RENS Technology Inc
  • Novartis AG
  • Teijin Pharma Ltd
  • VBS Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll